Compass Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, has recently released its 10-K report, revealing a focus on developing proprietary antibody-based therapeutics to treat various human diseases. The company's lead product candidates include tovecimig, CTX-471, and CTX-8371, targeting critical biological pathways required for an effective anti-tumor response. Founded in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics has incurred significant operating losses since its inception and has not generated any revenue. As of December 31, 2025, the company had an accumulated deficit of $431 million and $209 million in cash, cash equivalents, and marketable securities, with plans to fund operations into 2028.
In its 10-K report, Compass Therapeutics detailed its financial overview, indicating that it has funded its operations primarily through the sale of equity securities, raising $568 million through December 31, 2025. The company reported net losses of $66 million and $49 million for the years ended December 31, 2025 and 2024, respectively. It also highlighted the need for substantial additional funding to support its continuing operations and pursue its growth strategy. Compass Therapeutics anticipates incurring significant expenses for at least the next several years as it advances through clinical development and seeks regulatory approval for its product candidates.
Compass Therapeutics listed its shares on the Nasdaq Capital Market under the symbol “CMPX” on November 2, 2021. The company also engaged in a Private Investment in Public Entity (PIPE) offering, selling 25,000,000 shares of common stock at a purchase price of $3.21 per share, resulting in gross proceeds of $80.3 million. Additionally, the company entered into an At-The-Market (ATM) offering with Leerink Partners LLC and Cantor Fitzgerald & Co in 2025, terminating its prior Jefferies ATM Agreement. Moreover, in 2025, Compass Therapeutics conducted an underwritten offering, issuing 33,290,000 shares of common stock and pre-funded warrants, resulting in aggregate net proceeds of $129.3 million.
The company also addressed the Inflation Reduction Act of 2022, which imposes a 1% excise tax on share repurchases and introduces a 15% corporate alternative minimum tax on adjusted financial statement income, stating that it has not had a material impact on its consolidated financial statements to date.
Compass Therapeutics provided a breakdown of its results of operations, detailing research and development expenses primarily related to the development of its clinical product candidates, including milestone payments, employee-related expenses, CROs, and CDMOs. The company emphasized that the successful development and commercialization of its product candidates are highly uncertain due to the numerous risks and uncertainties associated with product development and commercialization. Additionally, the report outlined general and administrative expenses, including salaries, legal fees, professional fees, insurance costs, and other operating expenses, with an anticipation of increased expenses in the future. As a result of these announcements, the company's shares have moved -1.72% on the market, and are now trading at a price of $5.70. Check out the company's full 10-K submission here.
